Related Experiment Videos
[Longterm therapy and etofibrate (author's transl)]
MMW, Munchener Medizinische Wochenschrift
|January 18, 1980
Summary
Etofibrate effectively lowers cholesterol and triglyceride levels in patients with hyperlipoproteinemia. This potent hypolipidemic agent demonstrated good tolerance for long-term use without tachyphylaxis.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Hyperlipoproteinemia presents challenges in patient stabilization.
- Routine care parameters often require differentiation for effective management.
Purpose:
- To evaluate the efficacy and tolerance of etofibrate in difficult-to-stabilize hyperlipoproteinemic patients.
- To assess the impact of etofibrate on cholesterol, triglyceride, and other laboratory parameters.
Summary:
- Twenty patients with hyperlipoproteinemia (types IIa, IIb, IV) received 0.9 g of etofibrate daily.
- Treatment resulted in an 18% reduction in cholesterol and a 50% reduction in triglycerides.
- No tachyphylaxis was observed, and the drug was well-tolerated.
Impact:
- Etofibrate is a potent hypolipidemic agent suitable for long-term hyperlipoproteinemia management.
- Demonstrates significant lipid-lowering effects and good patient tolerance.